» Articles » PMID: 28302858

Reversion of Antibiotic Resistance in by Spiroisoxazoline SMARt-420

Abstract

Antibiotic resistance is one of the biggest threats to human health globally. Alarmingly, multidrug-resistant and extensively drug-resistant have now spread worldwide. Some key antituberculosis antibiotics are prodrugs, for which resistance mechanisms are mainly driven by mutations in the bacterial enzymatic pathway required for their bioactivation. We have developed drug-like molecules that activate a cryptic alternative bioactivation pathway of ethionamide in , circumventing the classic activation pathway in which resistance mutations have now been observed. The first-of-its-kind molecule, named SMARt-420 (Small Molecule Aborting Resistance), not only fully reverses ethionamide-acquired resistance and clears ethionamide-resistant infection in mice, it also increases the basal sensitivity of bacteria to ethionamide.

Citing Articles

Cyclophostin and Cyclipostins analogues counteract macrolide-induced resistance mediated by erm(41) in Mycobacterium abscessus.

Sarrazin M, Poncin I, Fourquet P, Audebert S, Camoin L, Denis Y J Biomed Sci. 2024; 31(1):103.

PMID: 39623375 PMC: 11613490. DOI: 10.1186/s12929-024-01091-w.


A Review of Antibacterial Candidates with New Modes of Action.

Butler M, Vollmer W, Goodall E, Capon R, Henderson I, Blaskovich M ACS Infect Dis. 2024; 10(10):3440-3474.

PMID: 39018341 PMC: 11474978. DOI: 10.1021/acsinfecdis.4c00218.


Synthesis, Activity, Toxicity, and In Silico Studies of New Antimycobacterial -Alkyl Nitrobenzamides.

Pais J, Antoniuk O, Pires D, Delgado T, Fortuna A, Costa P Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794178 PMC: 11124399. DOI: 10.3390/ph17050608.


Development of New Drugs to Treat Tuberculosis Based on the Dinitrobenzamide Scaffold.

Delgado T, Pais J, Pires D, Estrada F, Guedes R, Anes E Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794129 PMC: 11124350. DOI: 10.3390/ph17050559.


First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug.

Pieren M, Abaigar Gutierrez-Solana A, Antonijoan Arbos R, Boyle G, Davila M, Davy M J Antimicrob Chemother. 2024; 79(6):1353-1361.

PMID: 38656557 PMC: 11144484. DOI: 10.1093/jac/dkae107.